Long-acting ORKA-001 maintains deep psoriasis responses as Phase 3 planning approaches
ORKA-001 reaches 71.4% complete psoriasis clearance at Week 28 without redosing. See what the data mean for Oruka’s long-acting biologic strategy.
Features & Analysis